Real world treatment patterns and healthcare resource utilization (HRU) among chronic lymphocytic leukemia (CLL) patients by regimen.

被引：0
|
作者：
Byfield, Stacey DaCosta
Korrer, Stephanie
Ellis, Lorie
Schenkel, Brad
机构：
[1] OptumInsight, Eden Prairie, MN USA
[2] Optum, Eden Prairie, MN USA
[3] Janssen Sci Affairs LLC, Horsham, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e18043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18043
引用
收藏
页数：1
相关论文
共 50 条
  • [21] COMBINING PATIENTS' PERSPECTIVES AND TREATMENT/HEALTHCARE RESOURCE UTILIZATION IN CHRONIC LYMPHOCYTIC LEUKEMIA USING A NOVEL REAL-WORLD PATIENT-CENTERED DATABASE
    Kuk, D.
    Chen, B. P. H.
    Samyukta, N.
    Kudesia, V
    Talluri, T.
    Tsai, R.
    Goldberg, S.
    VALUE IN HEALTH, 2024, 27 (06) : S382 - S382
  • [22] REAL-WORLD EFFECTIVENESS AND TREATMENT PATTERNS OF VENETOCLAX-BASED REGIMENS AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN COMMUNITY SETTINGS
    Zakeri, M.
    Emechebe, N.
    Chowdhery, R.
    Jawaid, D.
    Alhasani, H.
    Manzoor, B. S.
    VALUE IN HEALTH, 2023, 26 (06) : S54 - S55
  • [23] Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax (VEN) or Chemotherapy (CT)/Chemoimmunotherapy (CIT)
    Nabhan, Chadi
    Mato, Anthony R.
    Kish, Jonathan K.
    Nero, Damion
    BLOOD, 2018, 132
  • [24] Real-World Treatment Patterns and Healthcare Resource Utilization (HRU) of Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
    Cheng, Wendy Y.
    Sarda, Sujata P.
    Mody-Patel, Nikita
    Krishnan, Sangeeta
    Yenikomshian, Mihran
    Scoble, Patrick J.
    Mahendran, Malena
    Lejeune, Dominique
    Yu, Louise
    Duh, Mei Sheng
    BLOOD, 2020, 136
  • [25] Clinical management of high risk chronic lymphocytic leukemia (CLL) with fludarabine, Rituxan® and cyclophosphamide (FRC) regimen.
    Shurafa, MS
    Wang, D
    VanDyke, D
    Maeda, K
    Alaman-Canoso, RT
    Janakiraman, N
    Nath, R
    Wiktor, A
    Baldy, C
    BLOOD, 2001, 98 (11) : 293B - 293B
  • [26] Real-world treatment patterns, health care resource utilization (HRU), and costs among patients with Waldenstrom macroglobulinemia (WM) initiating therapy
    Schenkel, Brad
    Ellis, Lorie
    Korrer, Stephanie
    Byfield, Stacey DaCosta
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
  • [27] Treatment patterns of newly diagnosed chronic lymphocytic leukemia (CLL) patients in the US
    Wang, Song
    Schenkel, Brad
    Wallace, Anna
    Chen, Yen Wen
    York, Whitney
    LEUKEMIA & LYMPHOMA, 2017, 58 : 87 - 87
  • [28] Characteristics and treatment patterns in patients newly diagnosed with chronic lymphocytic leukemia (CLL).
    Hess, G. P.
    Chen, C.
    Satram-Hoang, S.
    Reyes, C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Contemporary real-world treatment patterns of chronic lymphocytic leukaemia (CLL) in England
    Blak, B. T.
    Hori, S.
    Lock, K.
    Livings, C.
    Chen, C.
    Yong, A. S. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 213 - 214
  • [30] The economic benefits of time off treatment: real-world HRU, costs, and subsequent treatment with fixed duration venetoclax among patients with chronic lymphocytic leukemia
    Skarbnik, Alan
    Leslie, Lori A.
    Emechebe, Nnadozie
    Jawaid, Dureshahwar
    Manzoor, Beenish S.
    Alhasani, Hasan
    Hill, Brian
    LEUKEMIA & LYMPHOMA, 2023, 64 : S155 - S156
12345